Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1236)	7/7/2004 1:14:43 PM
From: Icebrg	Respond to of 1834

The state of GPCR research in 2004 The Nature Reviews Drug Discovery GPCR Questionnaire Participants [This is July's freebe at Nature Reviews - Drug discovery. A massive 50 page article]. As the largest class of cell-surface receptors, and the site of action for a large proportion of currently marketed drugs, G-protein-coupled receptors (GPCRs) are of substantial interest to researchers in both academia and industry. But for their potential as therapeutic targets to be fully realized, several questions about the biology of GPCRs need to be addressed. Here, we present the responses of 20 of the world’s leading authorities on GPCRs to 20 questions posed about the current state and future direction of the field. nature.com